BIOMEA FUSION INC (BMEA)
US09077A1060 - Common Stock
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage...
Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate
Preclinical data from ex vivo human islet experiments showed that icovamenib (BMF-219) was able to enhance the activity of glucagon-like peptide-1...
Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights
Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights
U.S. Food and Drug Administration (FDA) lifted Clinical Hold on COVALENT-111 (Type 2 Diabetes) & COVALENT-112 (Type 1 Diabetes) trialsCOVALENT-111...
Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219
Icovamenib is an oral covalent menin inhibitor in clinical development to investigate its impact on the function of insulin-producing beta cells
Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219
Icovamenib is an oral covalent menin inhibitor in clinical development to investigate its impact on the function of insulin-producing beta cells...
Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1
REDWOOD CITY, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company...
Noteworthy Wednesday Option Activity: BMEA, AUR, BBW
Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)
Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)
BMF-219 is an investigational oral covalent menin inhibitor developed to regenerate insulin-producing beta cells Two trial-in-progress oral presentations...
Noteworthy Tuesday Option Activity: BMEA, LLY, ASPN
Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts
International diabetes pioneers and thought leaders from 11 countries will work with Biomea leadership to unlock the potential of menin science and beta cell biology to advance BMF-219 and Biomea’s evolving pipeline
Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts
International diabetes pioneers and thought leaders from 11 countries will work with Biomea leadership to unlock the potential of menin science and beta...
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
REDWOOD CITY, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage...
Noteworthy Monday Option Activity: CVS, BMEA, BWXT
Notable Friday Option Activity: AMR, AAP, BMEA
Commit To Buy Biomea Fusion At $5, Earn 32% Using Options
Notable Thursday Option Activity: HA, SPOT, BMEA
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage...
BMEA Stock Earnings: Biomea Fusion Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biomea Fusion (NASDAQ:BMEA) just reported results for the second quarter of 202...
BMEA Stock Earnings: Biomea Fusion Beats EPS for Q2 2024
BMEA stock results show that Biomea Fusion beat analyst estimates for earnings per share the second quarter of 2024.
Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights
Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights
COVALENT-111 Phase 2b on track for Q4 2024 readoutCOVALENT-112 Phase 2a on track for Q4 2024 readoutAnnouncement of the third program in obesity on track...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biomea Fusion, Inc. - BMEA
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biomea Fusion, Inc. ("Biomea" or the "Company") (NASDAQ: BMEA). Such investors...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biomea Fusion, Inc. - BMEA
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biomea Fusion, Inc. ("Biomea" or the "Company") (NASDAQ: BMEA). Such investors...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biomea Fusion, Inc. - BMEA
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biomea Fusion, Inc. ("Biomea" or the "Company") (NASDAQ: BMEA). Such investors...
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Biomea Fusion, Inc. Investors to Inquire About Securities Class Action Investigation – BMEA
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Biomea Fusion, Inc. Investors to Inquire About Securities Class Action Investigation – BMEA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biomea Fusion, Inc. - BMEA
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biomea Fusion, Inc. ("Biomea" or the "Company") (NASDAQ: BMEA). Such investors...